Zynteglo Is Cost Effective At $2.1M, ICER Proposes; Validation For Bluebird’s Pivot To US?

 
• By Cathy Kelly
  
ICER Analysis Is Based On A Price Estimate For Zynteglo In US • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access